Salud financiera de hoja de balance de Aptose Biosciences

Salud financiera controles de criterios 3/6

Aptose Biosciences tiene un patrimonio de los accionistas total de $-2.9M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $13.0M y $15.9M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$9.25m
Patrimonio	-US$2.90m
Total pasivo	US$15.89m
Activos totales	US$12.99m

Actualizaciones recientes sobre salud financiera

Recent updates

Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents

Dec 08

Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data

Nov 12

Análisis de la situación financiera

Pasivos a corto plazo: APTO tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: APTO tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: APTO está libre de deudas.

Reducción de la deuda: APTO tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: APTO tiene suficiente cash runway para 2 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que APTO disponga de suficiente cash runway para 2 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Aptose Biosciences

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)

Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department Regarding Minimum Bid Price Requirement

Recent updates

Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024

Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024

Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC

Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.

New major risk - Shareholder dilution

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

New major risk - Share price stability

Independent Director recently bought US$53k worth of stock

Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib

New minor risk - Share price stability

Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.

Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Inc. Presents Highlights from Clinical Update

Aptose Biosciences Inc. announced that it expects to receive CAD 25 million in funding

Forecast to breakeven in 2025

Aptose Biosciences Inc. Updates Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

Aptose Biosciences Inc. Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Insufficient new directors

Aptose Biosciences Inc. to Report Q3, 2022 Results on Nov 01, 2022

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Biosciences Inc.’s New G3 Formulation of Luxeptinib Boosts Bioavailability

Aptose Biosciences Q2 2022 Earnings Preview

Aptose Biosciences Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department Regarding Minimum Bid Price Requirement

Aptose Biosciences Inc. to Report Q2, 2022 Results on Aug 02, 2022

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Aptose Appoints Fletcher Payne as Chief Financial Officer

Aptose Receives Fast Track Designation for Hm43239 in Relapsed/Refractory Aml Patients and Flt3 Mutation

Insufficient new directors

Aptose Biosciences Inc. to Report Q1, 2022 Results on May 09, 2022

Aptose Biosciences Inc. Announces Resignation of Dr. Jotin Marango as Chief Financial Officer

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

Aptose Biosciences Inc. Provides Update on APTO-253 Program

Independent Director recently bought US$316k worth of stock

Aptose Biosciences Inc. Announces HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

Insufficient new directors

Aptose: High Risk, High Reward. Watch Its Phase I Studies

Independent Director recently sold US$67k worth of stock

Aptose Biosciences (APTO) Presents Corporate Update at EHA 2021 - Slideshow

Aptose Presents Highlights from EHA2021 Virtual Congress During Corporate Update Event

Aptose Biosciences: An Assessment

Executive VP, Corporate Secretary, CFO & COO has left the company

Aptose Biosciences Inc. to Report Q4, 2020 Results on Mar 23, 2021

New 90-day low: US$3.98

Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents

New 90-day high: US$6.67

Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data

Aptose Biosciences Inc. to Present CG-806 and APTO-253 Data At the 2020 Ash Annual Meeting

Aptose Biosciences Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$4.75

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

New 90-day low - US$4.88

Aptose Biosciences Inc. to Report Q2, 2020 Results on Aug 04, 2020

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $55.125 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera